We are thrilled to announce that Advanced Virology has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the Centers for Disease Control and Prevention (CDC). This funding will enable us to build scalable, low-cost and high-efficiency reverse genetics platforms for large-volume production of virus stocks and derivative reagents — beginning with alphaviruses and influenza viruses.
- Our goal is to produce high-fidelity virus stocks at volumes researchers need, with consistency, efficiency, and rigorous quality control.
- The reverse genetics platforms will be engineered to manufacture virus stocks and derivative reagents for purchase by virologists in academia and industry.
- This SBIR Phase I award marks the beginning of what we believe will be transformative work in enabling low-cost production of large-volume virus stocks from reverse genetics systems.
We are grateful to the CDC for their support and belief in our vision. Over the next year, we will implement the design, testing, and validation phases, and we look forward to sharing updates as our R&D work progresses.